Caribou Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the Annual Meeting of Stockholders held by Caribou Biosciences, Inc. on June 17, 2026. The filing details the voting outcomes for four specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
- Proposal 1 (Election of Directors): All three Class II director nominees (Andrew Guggenheim, David Johnson, and Nancy Whiting) were elected. Each received approximately 31.5 to 31.7 million votes in favor, with roughly 9.4 to 9.6 million votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 67,457,482 for, 337,911 against, and 442,808 abstentions.
- Proposal 3 (Officer Exculpation Amendment): Stockholders did not approve the amendment to the Amended and Restated Certificate of Incorporation to provide for exculpation of officers from certain breaches of fiduciary duty. The vote was 37,483,637 for and 3,513,785 against.
- Proposal 4 (Adjournment): Stockholders approved the authority to adjourn the meeting if necessary to solicit further votes. However, the Company explicitly stated it decided not to adjourn the meeting despite the failure of Proposal 3.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors. The primary contingency noted is the failure of the officer exculpation amendment (Proposal 3), though the Company elected not to pursue further solicitation via adjournment.
Key Facts for Investor Verification
- Verify the implications of the failed vote on Proposal 3 regarding officer liability protections under Delaware law.
- Confirm the composition of the Board of Directors following the election of the three Class II nominees.
- Review the definitive proxy statement (Schedule 14A Amendment No. 1) filed on May 1, 2026, for detailed rationale behind the proposals.
- Note that the Company chose not to adjourn the meeting to seek additional votes for the failed amendment.